FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365512251> ?p ?o ?g. }

• W4365512251 endingPage "CT152" @default.
• W4365512251 startingPage "CT152" @default.
• W4365512251 abstract "Abstract Background: MET gene amplification is associated with poor prognosis in gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ). Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor. Here we reported the preliminary efficacy and safety from a phase 2 trial of savolitinib monotherapy in patients (pts) with MET-amplified advanced or metastatic GC/GEJ. (NCT04923932). Methods: Eligible pts had 2L+ GEJ or GC, with MET amplification and measurable lesions. Pts received savolitinib at 600 mg QD for body weight (BW) ≥50 kg, while 400 mg QD for BW &lt;50 kg in 21-day cycles until disease progression or meeting other criteria for end of treatment. Savolitinib BID regimen has also been additionally explored. The primary endpoint was objective overall response rate (ORR) evaluated by Independent Review Committee (IRC). One interim analysis (IA) was pre-defined at the first 20 QD pts who had at least 2 tumor assessments. Results: As of IA, 20 pts were enrolled for QD regimen. Demographics and clinical outcomes are shown in table 1. The mean relative dose intensity of 93.07%. Median duration of exposure was 2.09 months. Confirmed ORR by IRC was 45%, and reached 50% in 16 patients with MET GCN (high) while only 1 PR was observed in 4 patients with MET GCN (low). Duration of response rate at 4-month was 85.7% with median follow up time of 5.5 months. The most common Gr≥3 TRAE (≥5%) were platelet count decreased, hypersensitivity, anemia, neutropenia and hepatic function abnormal. In all pts, only 1 patient discontinued treatment due to grade 4 liver function abnormal (TRAE) and no patient died due to TRAE. Conclusion: Savolitinib monotherapy had manageable safety and showed promising efficacy in pts with MET-amplified GEJ or GC, particularly in pts with MET high GCN. BID regimen is being investigated to further evaluate the efficacy and safety of savolitinib in pts with MET high GCN. Table 1. Pts baseline characteristics and clinical efficacy Baseline Characteristics ITT in IA (n=20) Median age (min, max), yearsSex (male/female), nECOG (0/1/2)Median BMI (min, max), (kg/m2)Primary location of tumor (GC/GEJ)Tumor stage (IV)Prior line of therapy (1/2/≥3)MET GCN (high/low) 57.00 (39.5, 76.8)17/33/15/220.8 (14.9, 25.8)16/4205/10/516/4 Clinical Efficacy By IRC By Investigator Confirmed objective response rateDisease control rate4m-DoR rate,% (95% CI) 45%65%85.7 (33.4, 97.9) 40%55%71.4 (25.8, 92.0) Citation Format: Zhi Peng, Hua Wang, Baorui Liu, Huiting Xu, Zhenyang Liu, Tianshu Liu, Jun Zhang, Yuxian Bai, Ying Yuan, Tao Wu, Feng Ye, Qinghua Pan, Jufeng Wang, Enxiao Li, Diansheng Zhong, Yueyin Pan, Yanru Qin, Yan Yang, Yusheng Wang, Aiping Zhou, Yongshun Chen, Dianbao Zhang, Hongli Liu, Xiujuan Qu, Shubin Wang, Ning Liu, Jinsheng Wu, Wei Li, Kejun Nan, Hongming Pan, Jianming Xu, Chunmei Bai, Heling Liu, Jia Wei, Runzhi Chen, Rongrong Li, Wei Li, Jinghong Zhou, Hongyan Yin, Qian Xu, Songhua Fan, Yongxin Ren, Weiguo Su, Lin Shen. A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT152." @default.
• W4365512251 created "2023-04-15" @default.
• W4365512251 creator A5000432967 @default.
• W4365512251 creator A5000808913 @default.
• W4365512251 creator A5003463555 @default.
• W4365512251 creator A5004295637 @default.
• W4365512251 creator A5004716187 @default.
• W4365512251 creator A5006455181 @default.
• W4365512251 creator A5007278530 @default.
• W4365512251 creator A5008937427 @default.
• W4365512251 creator A5009977733 @default.
• W4365512251 creator A5012377236 @default.
• W4365512251 creator A5014377580 @default.
• W4365512251 creator A5015781606 @default.
• W4365512251 creator A5016717153 @default.
• W4365512251 creator A5016744541 @default.
• W4365512251 creator A5019840134 @default.
• W4365512251 creator A5024810594 @default.
• W4365512251 creator A5025855204 @default.
• W4365512251 creator A5029479913 @default.
• W4365512251 creator A5030200922 @default.
• W4365512251 creator A5037920295 @default.
• W4365512251 creator A5038853266 @default.
• W4365512251 creator A5042380657 @default.
• W4365512251 creator A5044410512 @default.
• W4365512251 creator A5044742215 @default.
• W4365512251 creator A5049634501 @default.
• W4365512251 creator A5050311492 @default.
• W4365512251 creator A5053725057 @default.
• W4365512251 creator A5057561820 @default.
• W4365512251 creator A5059732688 @default.
• W4365512251 creator A5061343828 @default.
• W4365512251 creator A5062014421 @default.
• W4365512251 creator A5068174848 @default.
• W4365512251 creator A5071250629 @default.
• W4365512251 creator A5071339229 @default.
• W4365512251 creator A5071672663 @default.
• W4365512251 creator A5072984329 @default.
• W4365512251 creator A5075996595 @default.
• W4365512251 creator A5083829548 @default.
• W4365512251 creator A5087160546 @default.
• W4365512251 creator A5087661837 @default.
• W4365512251 creator A5089073119 @default.
• W4365512251 creator A5090455356 @default.
• W4365512251 creator A5090539201 @default.
• W4365512251 date "2023-04-14" @default.
• W4365512251 modified "2023-10-17" @default.
• W4365512251 title "Abstract CT152: A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer" @default.
• W4365512251 doi "https://doi.org/10.1158/1538-7445.am2023-ct152" @default.
• W4365512251 hasPublicationYear "2023" @default.
• W4365512251 type Work @default.
• W4365512251 citedByCount "0" @default.
• W4365512251 crossrefType "journal-article" @default.
• W4365512251 hasAuthorship W4365512251A5000432967 @default.
• W4365512251 hasAuthorship W4365512251A5000808913 @default.
• W4365512251 hasAuthorship W4365512251A5003463555 @default.
• W4365512251 hasAuthorship W4365512251A5004295637 @default.
• W4365512251 hasAuthorship W4365512251A5004716187 @default.
• W4365512251 hasAuthorship W4365512251A5006455181 @default.
• W4365512251 hasAuthorship W4365512251A5007278530 @default.
• W4365512251 hasAuthorship W4365512251A5008937427 @default.
• W4365512251 hasAuthorship W4365512251A5009977733 @default.
• W4365512251 hasAuthorship W4365512251A5012377236 @default.
• W4365512251 hasAuthorship W4365512251A5014377580 @default.
• W4365512251 hasAuthorship W4365512251A5015781606 @default.
• W4365512251 hasAuthorship W4365512251A5016717153 @default.
• W4365512251 hasAuthorship W4365512251A5016744541 @default.
• W4365512251 hasAuthorship W4365512251A5019840134 @default.
• W4365512251 hasAuthorship W4365512251A5024810594 @default.
• W4365512251 hasAuthorship W4365512251A5025855204 @default.
• W4365512251 hasAuthorship W4365512251A5029479913 @default.
• W4365512251 hasAuthorship W4365512251A5030200922 @default.
• W4365512251 hasAuthorship W4365512251A5037920295 @default.
• W4365512251 hasAuthorship W4365512251A5038853266 @default.
• W4365512251 hasAuthorship W4365512251A5042380657 @default.
• W4365512251 hasAuthorship W4365512251A5044410512 @default.
• W4365512251 hasAuthorship W4365512251A5044742215 @default.
• W4365512251 hasAuthorship W4365512251A5049634501 @default.
• W4365512251 hasAuthorship W4365512251A5050311492 @default.
• W4365512251 hasAuthorship W4365512251A5053725057 @default.
• W4365512251 hasAuthorship W4365512251A5057561820 @default.
• W4365512251 hasAuthorship W4365512251A5059732688 @default.
• W4365512251 hasAuthorship W4365512251A5061343828 @default.
• W4365512251 hasAuthorship W4365512251A5062014421 @default.
• W4365512251 hasAuthorship W4365512251A5068174848 @default.
• W4365512251 hasAuthorship W4365512251A5071250629 @default.
• W4365512251 hasAuthorship W4365512251A5071339229 @default.
• W4365512251 hasAuthorship W4365512251A5071672663 @default.
• W4365512251 hasAuthorship W4365512251A5072984329 @default.
• W4365512251 hasAuthorship W4365512251A5075996595 @default.
• W4365512251 hasAuthorship W4365512251A5083829548 @default.
• W4365512251 hasAuthorship W4365512251A5087160546 @default.
• W4365512251 hasAuthorship W4365512251A5087661837 @default.
• W4365512251 hasAuthorship W4365512251A5089073119 @default.
• W4365512251 hasAuthorship W4365512251A5090455356 @default.
• W4365512251 hasAuthorship W4365512251A5090539201 @default.
• W4365512251 hasConcept C121608353 @default.
• W4365512251 hasConcept C126322002 @default.

• next